Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Agreement Across 10 Artificial Intelligence Models in Assessing Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Breast Cancer Whole-Slide Images.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026
Same author

Enhanced patient selection with quantitative continuous scoring of PD-L1 expression for IO treatment in metastatic NSCLC.

NPJ precision oncology·2025
Same author

Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Temporal Trends in Surgical Resection Rates and Biologic Prescribing in Crohn's Disease: A Population-based Cohort Study.

Journal of Crohn's & colitis·2020
Same author

Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.

Journal of Crohn's & colitis·2019

Related Experiment Video

Updated: Jun 4, 2026

Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

New IBD genetics: common pathways with other diseases.

C W Lees1, J C Barrett, M Parkes

  • 1Gastrointestinal Unit, Molecular Medicine Centre, University of Edinburgh, Edinburgh, UK. charlie.lees@ed.ac.uk

Gut
|February 9, 2011
PubMed
Summary

Genome-wide association studies have identified numerous genetic loci for inflammatory bowel diseases (IBDs). These studies reveal shared genetic susceptibility between IBD and other immune-mediated diseases, offering new therapeutic insights.

More Related Videos

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

Related Experiment Videos

Last Updated: Jun 4, 2026

Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

Area of Science:

  • Genetics
  • Immunology
  • Gastroenterology

Background:

  • Genome-wide association (GWA) studies have revolutionized complex disease genetics.
  • Inflammatory bowel diseases (IBDs), including Crohn's disease and ulcerative colitis, have yielded 99 susceptibility loci/genes through GWA studies.
  • Approximately one-third of identified loci confer susceptibility to both Crohn's disease and ulcerative colitis.

Purpose of the Study:

  • To review the genetic overlap between IBD and other diseases.
  • To discuss the implications of shared genetic susceptibility for pathogenesis and therapy.
  • To highlight the evolving understanding of IBD pathogenesis driven by genetic discoveries.

Main Methods:

  • Analysis of published genome-wide association study data for IBD.
  • Integration of epidemiological data on disease overlap.
  • Review of genetic associations related to immune signaling, autophagy, innate immunity, and barrier function.

Main Results:

  • Discovery of 99 susceptibility loci/genes for Crohn's disease and ulcerative colitis.
  • Identification of shared genetic factors, including those in IL23/Th17 signaling pathways.
  • Specific genetic associations for Crohn's disease (autophagy, innate immunity) and ulcerative colitis (barrier function).
  • Emerging theme of shared genetic susceptibility between IBD and other immune-mediated diseases, including diabetes mellitus.

Conclusions:

  • Genetic insights are transforming the understanding of complex diseases like IBD.
  • Shared genetic architecture between IBD and other diseases suggests common pathogenic mechanisms.
  • Further research into genetic overlaps promises to advance IBD pathogenesis understanding and therapeutic strategies.